DECADERM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DECADERM (DECADERM).
Dexamethasone acts as a glucocorticoid receptor agonist, binding to the cytoplasmic glucocorticoid receptor, leading to modulation of gene transcription, suppression of pro-inflammatory cytokines, and induction of anti-inflammatory proteins, thereby reducing inflammation and immune responses.
| Metabolism | Primarily hepatic via cytochrome P450 3A4 (CYP3A4) to inactive metabolites. Dexamethasone itself can induce CYP3A4. |
| Excretion | Renal (primarily as inactive metabolites, <5% unchanged), fecal/biliary (<2%). |
| Half-life | Terminal elimination half-life approximately 36–54 hours (mean 44 h); prolonged in hepatic impairment. |
| Protein binding | 77% bound to corticosteroid-binding globulin and albumin. |
| Volume of Distribution | 0.5–1.0 L/kg; distributes into all body tissues and crosses the placenta. |
| Bioavailability | Oral: 40–60%; topical: 1% (varies with skin integrity); intramuscular: 100%. |
| Onset of Action | Oral: 1–2 hours; topical: 2–7 days for psoriasis; injection: 24–48 hours. |
| Duration of Action | Single dose: 2–3 days (suppression of HPA axis persists for 1–2 weeks after prolonged therapy). |
| Brand Substitutes | Dava Derm Cream, Dermi 5 Cream, Dermigo 5 Cream, Dermifree Cream, Dermicraft 5C Cream |
DECADERM (dexamethasone) is typically administered as 0.75-9 mg/day orally in divided doses every 6-12 hours, depending on the condition. For acute indications, higher doses (up to 40 mg/day) may be given intravenously or intramuscularly.
| Dosage form | GEL |
| Renal impairment | No specific dose adjustment is required for renal impairment as dexamethasone is primarily metabolized hepatically. However, patients with severe renal impairment (eGFR < 30 mL/min) should be monitored for fluid retention and electrolyte disturbances. |
| Liver impairment | For Child-Pugh Class A: no adjustment. For Child-Pugh Class B: consider a 50% dose reduction. For Child-Pugh Class C: use with caution, consider a 50-75% dose reduction and monitor for adverse effects. |
| Pediatric use | Pediatric dosing is weight-based: 0.08-0.3 mg/kg/day orally or intravenously divided every 6-12 hours. Maximum dose should not exceed adult dose. For specific conditions (e.g., croup), a single dose of 0.6 mg/kg may be used. |
| Geriatric use | Elderly patients may require lower starting doses due to increased sensitivity to corticosteroids. Consider initiating at the lowest effective dose and titrating slowly. Monitor for osteoporosis, hyperglycemia, and electrolyte imbalances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DECADERM (DECADERM).
| Breastfeeding | Dexamethasone is excreted into breast milk; M/P ratio is approximately 0.5-1.0. Low to moderate doses are considered compatible with breastfeeding. However, higher doses may suppress infant adrenal function. Monitor infant for growth and adrenal suppression if maternal dose exceeds physiological replacement. |
| Teratogenic Risk | Topical corticosteroids are generally considered low risk in pregnancy due to minimal systemic absorption. However, for DECADERM (dexamethasone), systemic exposure increases risk of orofacial clefts (first trimester), intrauterine growth restriction, and fetal adrenal suppression (second/third trimester). Use only if benefit outweighs risk. |
■ FDA Black Box Warning
Corticosteroids, including dexamethasone, may increase the risk of serious and potentially fatal infections (e.g., bacterial, viral, fungal, parasitic, and opportunistic infections). They can also mask signs of infection. Avoid live vaccines during therapy.
| Serious Effects |
["Hypersensitivity to dexamethasone or any component of the formulation.","Systemic fungal infections (except for severe hypersensitivity reactions).","Administration of live or live-attenuated vaccines.","Idiopathic thrombocytopenic purpura (for intramuscular administration)."]
| Precautions | ["Systemic corticosteroid use may lead to immunosuppression, increased infection risk, and reactivation of latent infections (e.g., tuberculosis, hepatitis B).","Adrenal suppression and withdrawal symptoms upon abrupt discontinuation; need for gradual taper.","Increased risk of gastrointestinal perforation in conditions like diverticulitis or peptic ulcer disease.","Osteoporosis and increased fracture risk with long-term use.","Ocular effects: posterior subcapsular cataracts, glaucoma, exacerbation of fungal infections.","Neuropsychiatric effects: mood swings, psychosis, euphoria, depression.","Endocrine effects: hyperglycemia, diabetes mellitus, Cushing's syndrome.","Cardiovascular effects: hypertension, fluid retention, increased risk of thromboembolism.","Monitor growth in pediatric patients; use in pregnancy only if benefit outweighs risk."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. Fetal monitoring includes serial growth ultrasounds for intrauterine growth restriction. If used near term, monitor neonatal adrenal function. |
| Fertility Effects | Dexamethasone may affect fertility by inhibiting pituitary-adrenal axis, potentially causing menstrual irregularities or ovulation suppression. Reversible upon discontinuation. |